 KLS
Main Page |
KLS
Conference Index |
Home |
Last
Update:
December 08, 2014
 Posters identified with this
icon are in Portable Document
Format (PDF) and
require the
Adobe Acrobat Reader 5
.
|
| In Vitro Studies |
|
CONFERENCE
POSTER
CONFERENCE
POSTER
|
| Viral Dynamics/Response Data |
|
CONFERENCE
POSTER
Failure to Achieve HIV RNA less than 3 Copies/mL Does Not Predict Loss of Virologic Response to Kaletra (Lopinavir/Ritonavir) Therapy through 3 Years L. PERRIN, M. KING, S. BRUN et al. PDF Poster
Abstract
|
| Drug Interactions |
|
Impact of
ABT 378/r on the Amprenavir (APV) Plasma Concentrations in HIV-Experienced Patients Treated by the Association APV –ABT378/r J. L. MEYNARD, J. M. POIRIER, J. B. GUIARD-SCHMID, et al Abstract |
| Resistance/Cross Resistance |
|
CONFERENCE POSTER
Comparison of the Emergence of Resistance in a Blinded Phase III Study with Kaletra (Lopinavir/Ritonavir) or Nelfinavir Plus d4T/3TC from Week 24 through 96 B. BERNSTEIN, D. KEMPF, M. KING, et al. PDF Poster
Quantitation of Lopinavir Resistance and Cross-Resistance and Phenotypic Contribution of Mutations Shared with Other Protease Inhibitors P. R. HARRIGAN, C. VAN DEN EYNDE, B. A. LARDER. et al. Abstract |
| Efficacy |
|
CONFERENCE
POSTER Pre-Registrational Use of ABT 378/r in Heavily-Experienced Patients: the French ATU Program Experience I COHEN-CODAR, F BOER, R TERRIER et al. PDF Poster
Abstract
|
| Adolescent/Adult Therapeutic Indications/Strategies |
|
CONFERENCE POSTER Kaletra (lopinavir/ritonavir) and Efavirenz: 72 Week Safety/Efficacy Evaluation and Phenotypic/Genotypic Breakpoints in Multiple PI Experienced Patients S. DANNER, S. BRUN, J. SYLTE, J, et al. PDF Poster
Abstract
|
|
CONFERENCE POSTER Comparison of the Emergence of Resistance in a Blinded Phase III Study with Kaletra (Lopinavir/Ritonavir) or Nelfinavir Plus d4T/3TC from Week 24 through 96 B. BERNSTEIN, D. KEMPF, M. KING, et al. PDF Poster
Abstract
|
|
KLS
Main Page |
KLS
Conference Index |
Home |
|
Kaletra Library Service |
